Tonix Pharmaceuticals Holding (TNXP) Long-Term Debt Repayments (2012 - 2025)
Tonix Pharmaceuticals Holding (TNXP) posted Long-Term Debt Repayments of $9.6 million for Q1 2025, up 1268.79% on a QoQ basis from $705000.0 in Q4 2024, and up 4006.38% year-over-year from $235000.0 in Q1 2024.
Analysis
Tonix Pharmaceuticals Holding (TNXP) Long-Term Debt Repayments (2012 - 2025) Analysis & Trends
Tonix Pharmaceuticals Holding has reported Long-Term Debt Repayments for 3 years, with the latest figure at $9.6 million in Q1 2025.
- On a quarterly basis, Long-Term Debt Repayments rose 4006.38% year-over-year to $9.6 million in Q1 2025; TTM through Dec 2025 was $9.6 million, a 310.64% increase from a year earlier, with the FY2025 full-year figure at $9.6 million, up 310.64% from the prior year.
- Long-Term Debt Repayments was $9.6 million for Q1 2025 at Tonix Pharmaceuticals Holding, up from $705000.0 in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $9.6 million in Q1 2025, with the low at $235000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 2.00 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 5.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 17.05 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | Tonix Pharmaceuticals Holding | 220.65 Mn | 220.65 Mn | 12.84 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 9.65 Mn |
| Dec 31, 2024 | 705,000.00 |
| Sep 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 705,000.00 |
| Mar 31, 2024 | 235,000.00 |
| Mar 31, 2012 | 150,000.00 |